Appeal No. 2000-0630
Application No. 07/780,717
have addressed the propriety of this combination. As matters now stand, the issues
before us for review are as follows:
(I) The rejection of claims 39 through 45, 47 through 54, 56 through 58 and 60
through 65 under 35 U.S.C. § 103(a) as unpatentable over Hendrickson, Sano, Kenten,
Shoemaker, Tolman, Lowenadler and Meade.
(II) The rejection of claims 39 through 45, 47 through 54, 56 through 58 and 60
through 65 under 35 U.S.C. § 103(a) as unpatentable over Rodwell, Hendrickson, Sano,
Kenten, Shoemaker, Tolman, Lowenadler and Meade.
(III) The rejection of claim 68 under 35 U.S.C. § 103(a) as unpatentable over
Hendrickson and Sano.
For the reasons discussed in the body of this opinion, we reverse all three of the
examiner’s rejections.
BACKGROUND
Streptavidin is a protein which binds rapidly and with high affinity to any molecule
which contains unhindered biotin (specification, page 2), and streptavidin-containing
chimeric proteins can be specifically detected and isolated by their ability to bind biotin
(specification, pages 13-14). Native streptavidin has 159 amino acid residues, but,
according to the specification, most commercial preparations contain “core” streptavidin
with a total of 125 to 127 residues (page 11). Core streptavidin has a much higher
solubility in water than native streptavidin (Id.).
5
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007